

Commissioner for Patenes, Box PC7 In fed States Patent and Trademaik Office Washington D.C. 2020 www.usplo.gov

TORSE NAMED APPELLAND

ATTA DIRECTOR

09/719053

MONTREAL, PQC H3A 2 Y3

SULLIVAN

R

13045-2US-1

INTERNATIONAL APPLICATION NO PCT/CA99/00437

SWABEY OGILVY RENAULT **SUITE 1600** 1981 MCGILL COLLEGE AVENUE

N 1008 - NO

13 MAY 99

08 JUN 98

DATE MAILER 09 APR 2001

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

1. The following items have been submitted by the applicant or the IB to the United States Patent and Trademark a Designated Office (37 CFR 1.494) 🗶 an Elected Office (37 CFR 1.495) Office as

🗶 U.S. Basic National Fee

💉 Indication of Small Entity Status

x. Copy of the international application.

Translation of the international application into English

Oath or Declaration of inventors(s).

Translation of Article 19 amendments into English.

Copy of Article 19 amendments.

× Other.

* Priority Document

x The International Preliminary Examination Report in English and its Annexes, if any Translation of Annexes to the International Preliminary Examination Report into English

- Applicant has requested early processing under 35 U.S.C. 371(f) but has not filed the following indicated items and/or the indicated items in paragraph 3 below. The Basic National Fee and the copy of the international application must be filed prior to 20 or 30 months from the priority date to avoid abandonment
 - U.S. Basic National Fee.

Copy of the international application.

- 3 The following items MUST be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371.
 - a Translation of the application into English. A processing fee will be required if submitted later than the appropriate 20 or 30 months from the priority date The current translation is defective for the reasons indicated on the attached Notice of Defective Translation
 - b. Processing fee for providing the translation of the application and or the Annexes later than the appropriate 20 or 30 months from the priority date (37 CFR 1 492(t)).
 - c. Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), properly identifying the application (preferably by the International application number and international filing date). A surcharge will be required if submitted later than the appropriate 20 or 30 months from the prior;ty

The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) for the reasons indicated on the attached PCT DO EO 917.

- d. Surcharge for providing the oath or declaration later than the appropriate 20 or 30 months from the priority date (37 CFR 1 492(e)).
- 4. Additional claim fees of \$ as a large entity small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due (37 CFR 1 492(g)). See attached PTO-875
- 5 x Applicant has not submitted the required sequence listing pursuant to 37 CFR 1 821 1 825. See attached PCT: DO 'EO '920

ALL OF THE ITEMS SET FORTH IN 3(a)-3(d), 4 AND 5 ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 22 OR 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR

6. If pox 34 or 3c is checked, a translation of the Annexes MUST be submitted no later than the time period set above or the Amexes will be cancelled. A processing fee will be required it submitted later than 20 or 30 months from the priority date The Article 19 amendments are cancelled since a translation was not provided by the appropriate 20 (37 CFR | 494(d)) or 30 (37 CFR I 495(d)) months from the priority date.

Applicant is reminded that any communication to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with this response.

Friclosed PCT DO FO 91

¿ PCT DO FO 920

Notice of Detective Translation

PTO 875 FORM PCT DO FO 905 (March 2001).

Barbara A. Campbell

Telephone 703-305-3631

Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D.C., 2023* www.uspto.gov

No. 180° 2 183

09/719053

1981 MCGILL COLLEGE AVENUE

SWABEY ÖGILVY RENAULT

MONTREAL, PQC H3A 2 Y3

SAPPLE AREAS

SUITE 1600

SULLIVAN

R

13045-2US-1

INTERNAZIONAL APPET ATION NO

PCT/CA99/00437

g A construction

TRUBELLY DALLS

13 MAY 99

08 JUN 98

MACL MACLED

0 9 APR 2001

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- The application fails to comply with the requirements of 37 CFR 1.821-1.825. This application does not contain, a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c). A copy of the "Sequence Listing" in computer readable format has not been submitted as required by 37 CFR 1.821(e).
- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."

The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d). The paper copy or compact disc of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Other:

APPLICANT MUST PROVIDE:

An initial or substitute computer readable form (CRF) of the "Sequence Listing."

An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.

A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CALL:

- (703) 308-4216, for Rules interpretation,
- (703) 308-4212, for CRF submission help,
- (703) 287-0200, for Patentln software help.

Barbara A. Campbell Telephone: 703-305-3631

Application No.. 09/719,053

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	1.	This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2.	This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3.	A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4.	A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5.	The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6.	The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
X	7.	Other: SEQ ID NO is required on page 7, line 31.
Applicant Must Provide:		
X	Αı	n initial or <u>substitute</u> computer readable form (CRF) copy of the "Sequence Listing".
X		n initial or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amendment directing its entry to the specification.
X	ap	statement that the content of the paper and computer readable copies are the same and, where oplicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 825(b) or 1.825(d).
For	q	uestions regarding compliance to these requirements, please contact:
For	C er	Rules Interpretation, call (703) 308-4216 RF Submission Help, call (703) 308-4212 htln Software Program Support (SIRA) Fechnical Assistance703-287-0200
		To Purchase Patentin Software 703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE